Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer

Bacillus Calmette-Guérin (BCG) therapy for patients with non-muscle invasive bladder cancer (NMIBC) faces limitations in efficacy and significant side effects, aggravated by a recent global shortage. In this prospective clinical study, we report the outcomes of sequential intravesical administration...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Mirko Bakula, Tvrtko Hudolin, Nikola Knezevic, Zoran Zimak, Jerko Andelic, Ilija Juric, Marija Gamulin, Milena Gnjidic, Zeljko Kastelan
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2024-06-01
Schriftenreihe:	Life
Schlagworte:	BCG shortage non-muscle invasive bladder cancer BCG-naïve docetaxel gemcitabine
Online-Zugang:	https://www.mdpi.com/2075-1729/14/7/789
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!